Cargando…
Clonal evolution characteristics and reduced dimension prognostic model for non-metastatic metachronous bilateral breast cancer
BACKGROUND: How to evaluate the prognosis and develop overall treatment strategies of metachronous bilateral breast cancer (MBBC) remains confused in clinical. Here, we investigated the correlation between clonal evolution and clinical characteristics of MBBC; we aim to establish a novel prognostic...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559188/ https://www.ncbi.nlm.nih.gov/pubmed/36249030 http://dx.doi.org/10.3389/fonc.2022.963884 |
_version_ | 1784807601600462848 |
---|---|
author | Li, Lingyu Li, Jiaxuan Jia, Jiwei He, Hua Li, Mingyang Yan, Xu Yu, Qing Guo, Hanfei Wang, Hong Lv, Zheng Sun, Haishuang Liao, Guidong Cui, Jiuwei |
author_facet | Li, Lingyu Li, Jiaxuan Jia, Jiwei He, Hua Li, Mingyang Yan, Xu Yu, Qing Guo, Hanfei Wang, Hong Lv, Zheng Sun, Haishuang Liao, Guidong Cui, Jiuwei |
author_sort | Li, Lingyu |
collection | PubMed |
description | BACKGROUND: How to evaluate the prognosis and develop overall treatment strategies of metachronous bilateral breast cancer (MBBC) remains confused in clinical. Here, we investigated the correlation between clonal evolution and clinical characteristics of MBBC; we aim to establish a novel prognostic model in these patients. METHODS: The data from Surveillance, Epidemiology, and End Results (SEER) database and the First Hospital of Jilin University were analyzed for breast cancer–specific cumulative mortality (BCCM) by competing risk model. Meanwhile, whole-exome sequencing was applied for 10 lesions acquired at spatial–temporal distinct regions of five patients from our own hospital to reconstruct clonal evolutionary characteristics of MBBC. Then, dimensional-reduction (DR) cumulative incidence function (CIF) curves of MBBC features were established on different point in diagnostic interval time, to build a novel DR nomogram. RESULTS: Significant heterogeneity in genome and clinical features of MBBC was widespread. The mutational diversity of contralateral BC (CBC) was significantly higher than that in primary BC (PBC), and the most effective prognostic MATH ratio was significantly correlated with interval time (R (2) = 0.85, p< 0.05). In SEER cohort study (n = 13,304), the interval time was not only significantly affected the BCCM by multivariate analysis (p< 0.000) but determined the weight of clinical features (T/N stage, grade and ER status) on PBC and CBC in prognostic evaluation. Thus, clinical parameters after DR based on interval time were incorporated into the nomogram for prognostic predicting BCCM. Concordance index was 0.773 (95% CI, 0.769–0.776) in training cohort (n = 8,869), and 0.819 (95% CI, 0.813–0.826) in validation cohort (n = 4,435). CONCLUSIONS: Bilateral heterogeneous characteristics and interval time were determinant prognostic factors of MBBC. The DR prognostic nomogram may help clinicians in prognostic evaluation and decision making. |
format | Online Article Text |
id | pubmed-9559188 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95591882022-10-14 Clonal evolution characteristics and reduced dimension prognostic model for non-metastatic metachronous bilateral breast cancer Li, Lingyu Li, Jiaxuan Jia, Jiwei He, Hua Li, Mingyang Yan, Xu Yu, Qing Guo, Hanfei Wang, Hong Lv, Zheng Sun, Haishuang Liao, Guidong Cui, Jiuwei Front Oncol Oncology BACKGROUND: How to evaluate the prognosis and develop overall treatment strategies of metachronous bilateral breast cancer (MBBC) remains confused in clinical. Here, we investigated the correlation between clonal evolution and clinical characteristics of MBBC; we aim to establish a novel prognostic model in these patients. METHODS: The data from Surveillance, Epidemiology, and End Results (SEER) database and the First Hospital of Jilin University were analyzed for breast cancer–specific cumulative mortality (BCCM) by competing risk model. Meanwhile, whole-exome sequencing was applied for 10 lesions acquired at spatial–temporal distinct regions of five patients from our own hospital to reconstruct clonal evolutionary characteristics of MBBC. Then, dimensional-reduction (DR) cumulative incidence function (CIF) curves of MBBC features were established on different point in diagnostic interval time, to build a novel DR nomogram. RESULTS: Significant heterogeneity in genome and clinical features of MBBC was widespread. The mutational diversity of contralateral BC (CBC) was significantly higher than that in primary BC (PBC), and the most effective prognostic MATH ratio was significantly correlated with interval time (R (2) = 0.85, p< 0.05). In SEER cohort study (n = 13,304), the interval time was not only significantly affected the BCCM by multivariate analysis (p< 0.000) but determined the weight of clinical features (T/N stage, grade and ER status) on PBC and CBC in prognostic evaluation. Thus, clinical parameters after DR based on interval time were incorporated into the nomogram for prognostic predicting BCCM. Concordance index was 0.773 (95% CI, 0.769–0.776) in training cohort (n = 8,869), and 0.819 (95% CI, 0.813–0.826) in validation cohort (n = 4,435). CONCLUSIONS: Bilateral heterogeneous characteristics and interval time were determinant prognostic factors of MBBC. The DR prognostic nomogram may help clinicians in prognostic evaluation and decision making. Frontiers Media S.A. 2022-09-29 /pmc/articles/PMC9559188/ /pubmed/36249030 http://dx.doi.org/10.3389/fonc.2022.963884 Text en Copyright © 2022 Li, Li, Jia, He, Li, Yan, Yu, Guo, Wang, Lv, Sun, Liao and Cui https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Li, Lingyu Li, Jiaxuan Jia, Jiwei He, Hua Li, Mingyang Yan, Xu Yu, Qing Guo, Hanfei Wang, Hong Lv, Zheng Sun, Haishuang Liao, Guidong Cui, Jiuwei Clonal evolution characteristics and reduced dimension prognostic model for non-metastatic metachronous bilateral breast cancer |
title | Clonal evolution characteristics and reduced dimension prognostic model for non-metastatic metachronous bilateral breast cancer |
title_full | Clonal evolution characteristics and reduced dimension prognostic model for non-metastatic metachronous bilateral breast cancer |
title_fullStr | Clonal evolution characteristics and reduced dimension prognostic model for non-metastatic metachronous bilateral breast cancer |
title_full_unstemmed | Clonal evolution characteristics and reduced dimension prognostic model for non-metastatic metachronous bilateral breast cancer |
title_short | Clonal evolution characteristics and reduced dimension prognostic model for non-metastatic metachronous bilateral breast cancer |
title_sort | clonal evolution characteristics and reduced dimension prognostic model for non-metastatic metachronous bilateral breast cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559188/ https://www.ncbi.nlm.nih.gov/pubmed/36249030 http://dx.doi.org/10.3389/fonc.2022.963884 |
work_keys_str_mv | AT lilingyu clonalevolutioncharacteristicsandreduceddimensionprognosticmodelfornonmetastaticmetachronousbilateralbreastcancer AT lijiaxuan clonalevolutioncharacteristicsandreduceddimensionprognosticmodelfornonmetastaticmetachronousbilateralbreastcancer AT jiajiwei clonalevolutioncharacteristicsandreduceddimensionprognosticmodelfornonmetastaticmetachronousbilateralbreastcancer AT hehua clonalevolutioncharacteristicsandreduceddimensionprognosticmodelfornonmetastaticmetachronousbilateralbreastcancer AT limingyang clonalevolutioncharacteristicsandreduceddimensionprognosticmodelfornonmetastaticmetachronousbilateralbreastcancer AT yanxu clonalevolutioncharacteristicsandreduceddimensionprognosticmodelfornonmetastaticmetachronousbilateralbreastcancer AT yuqing clonalevolutioncharacteristicsandreduceddimensionprognosticmodelfornonmetastaticmetachronousbilateralbreastcancer AT guohanfei clonalevolutioncharacteristicsandreduceddimensionprognosticmodelfornonmetastaticmetachronousbilateralbreastcancer AT wanghong clonalevolutioncharacteristicsandreduceddimensionprognosticmodelfornonmetastaticmetachronousbilateralbreastcancer AT lvzheng clonalevolutioncharacteristicsandreduceddimensionprognosticmodelfornonmetastaticmetachronousbilateralbreastcancer AT sunhaishuang clonalevolutioncharacteristicsandreduceddimensionprognosticmodelfornonmetastaticmetachronousbilateralbreastcancer AT liaoguidong clonalevolutioncharacteristicsandreduceddimensionprognosticmodelfornonmetastaticmetachronousbilateralbreastcancer AT cuijiuwei clonalevolutioncharacteristicsandreduceddimensionprognosticmodelfornonmetastaticmetachronousbilateralbreastcancer |